Major Phase III studies were planned to address basic issues regarding the
effectiveness and safety of alendronate. However, 3 special studies were de
signed to provide information regarding the effectiveness and safety of ale
ndronate therapy for postmenopausal osteoporosis that complement the result
of the large Phase III osteoporosis trials, addressing the duration of the
drug's antiresorptive effect after withdrawal of therapy the effects of al
endronate therapy in more elderly subjects and a comparison of alendronate
with another treatment for osteoporosis.